Item 2.01. Completion of Acquisition or Disposition of Assets

On June 25, 2009, Technitrol, Inc. ("Technitrol") through its wholly-owned subsidiaries completed the disposition of its Medtech components business ("Medtech") to Xilco A/S ("Xilco"). The purchase price paid in cash at closing was approximately $201 million and is subject to final working capital and financial indebtedness adjustments.

The foregoing summary is not complete and is qualified in its entirety by reference to the full text of the Share Purchase Agreement filed as Exhibit 2.1 to Technitrol's Form 8-K filed on June 8, 2009 which is incorporated herein by reference. Investors in Technitrol and other persons not party to the Share Purchase Agreement should not for any purpose rely on the covenants, representations or warranties made in it, or consider them as statements of fact or as representing the current state of Technitrol's affairs.

Item 9.01. Financial Statements and Exhibits

(b) Pro Forma Financial Information.

The unaudited pro forma statements of operations for the year ended December 26, 2008 and the three months ended March 27, 2009 and the unaudited pro forma balance sheet as of March 27, 2009 are attached hereto as Exhibit 99.1. The unaudited pro forma consolidated statements of operations and consolidated balance sheet that have been prepared by management do not exclude cost savings from operational efficiencies, revenue synergies or operating strategies employed prior to the disposition. Therefore, the pro forma financial information is not necessarily indicative of the operating results that Technitrol would have achieved had the disposition occurred on December 29, 2007 or Technitrol's financial position had the disposition occurred on March 27, 2009 and should not be construed as a representation of Technitrol's future operating results or financial position. Such information should be read in conjunction with the historical financial statements of Technitrol.

(d) Exhibits.

99.1 Pro Forma Financial Information.